MiddleBrook Pharmaceuticals, DoctorDirectory.com enter into agreement to expand IncreaseRx promotion program

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner for MOXATAG (amoxicillin extended-release) Tablets, 775 mg, to expand its previously announced IncreaseRx® promotion program. The expanded IncreaseRx® promotion program for MOXATAG will incorporate physicians previously detailed by the Company’s field sales force. IncreaseRx® performs as a virtual contract sales organization, providing health care professionals with access to electronic sampling, electronic learning and online educational tools. The expanded IncreaseRx® promotion program for MOXATAG will utilize web-based educational and promotional tactics to reach prescribers with targeted MOXATAG sales and marketing messages.

“We look forward to providing a promotional boost for MOXATAG through IncreaseRx® and providing increased access to MOXATAG samples and information to physicians nationwide.”

Dave Becker, acting president and chief executive officer of MiddleBrook said, “Under this expanded IncreaseRx® program, physicians who previously received MOXATAG samples and information from MiddleBrook field sales representatives will be able to request samples and receive important product information electronically. We will be able to reach more than 150,000 physicians across the nation through the expanded IncreaseRx® program for MOXATAG.”

Jay Grobowsky, president and CEO of DoctorDirectory, said, “We look forward to providing a promotional boost for MOXATAG through IncreaseRx® and providing increased access to MOXATAG samples and information to physicians nationwide.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Imlunestrant offers new hope for ER-positive HER2-negative breast cancer